Compare
Relmada Therapeutics, Inc. vs Journey Medical Corp vs Arbutus Biopharma Corp vs Eton Pharmaceuticals, Inc.
| Latest fiscal year | Relmada Therapeutics, Inc. RLMD | Journey Medical Corp DERM | Arbutus Biopharma Corp ABUS | Eton Pharmaceuticals, Inc. ETON |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $61.24M | $14.08M | $79.95M |
| Revenue growth (YoY) | n/a | +11.1% | +128.2% | +104.9% |
| Gross margin | n/a | 65.8% (computed) | n/a | 53.5% |
| Operating margin | n/a | -13.3% | -271.0% | -1.1% |
| Net margin | n/a | -18.7% | -237.9% | -5.8% |
| Net income | -$57.39M | -$11.43M | -$33.50M | -$4.60M |
| EPS (Diluted) | -$1.45 | -$0.47 | -$0.17 | n/a |
| Operating cash flow | -$45.79M | -$12.44M | -$39.64M | $10.52M |
| Free cash flow | n/a | n/a | -$39.64M | $10.19M |
| Cash & equivalents | $3.50M | $24.09M | $18.01M | $25.94M |
| Total assets | $94.00M | $94.59M | $94.62M | $92.11M |
| Total liabilities | $7.49M | $62.74M | $18.04M | $65.96M |
| Shareholders' equity | $86.51M | $31.85M | $76.58M | $26.15M |
| Return on year-end equity | -66.3% | -35.9% | -43.7% | -17.6% |
| Shares outstanding | 73.33M | n/a | 192.53M | 27.05M |
Revenue, most recent five fiscal years
| Fiscal year | Relmada Therapeutics, Inc. | Journey Medical Corp | Arbutus Biopharma Corp | Eton Pharmaceuticals, Inc. |
|---|---|---|---|---|
| Latest | $5.1K Ended 2013-08-31 | $61.24M Ended 2025-12-31 | $14.08M Ended 2025-12-31 | $79.95M Ended 2025-12-31 |
| 1 year earlier | $7.9K Ended 2012-08-31 | $55.13M Ended 2024-12-31 | $6.17M Ended 2024-12-31 | $39.01M Ended 2024-12-31 |
| 2 years earlier | n/a | $59.66M Ended 2023-12-31 | $18.14M Ended 2023-12-31 | $31.64M Ended 2023-12-31 |
| 3 years earlier | n/a | $71.00M Ended 2022-12-31 | $39.02M Ended 2022-12-31 | $21.25M Ended 2022-12-31 |
| 4 years earlier | n/a | $63.13M Ended 2021-12-31 | $10.99M Ended 2021-12-31 | $21.83M Ended 2021-12-31 |